Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)

Exclusion Criteria

• •1. Prior treatment with dupilumab (REGN668/ SAR231893)
• •2. Patients needing \>10 mg of daily prednisone (including equivalent doses of other steroids) or high dose systemic corticosteroids (≥2 mg/kg) for 14 days or longer during the 16 week treatment period of the study
• •3. History of Guillain-Barre syndrome
• •4. History of severe allergic reaction to either vaccine or to vaccine components including alum, thimerosal, phenol
• •5. Patients with a severe reaction to natural rubber latex products (some packaging components of the vaccines contain rubber latex and may cause a reaction in susceptible individuals)
• •6. Treatment with biologics within 4 months of baseline visit
• •7. Chronic or acute infection requiring treatment with antibiotics, antivirals, antiparasitics, antifungals within 4 weeks before screening visit or superficial skin infections within 1 week of screening visit